Cargando…
A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine
A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disea...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766959/ https://www.ncbi.nlm.nih.gov/pubmed/33348607 http://dx.doi.org/10.3390/vaccines8040771 |
_version_ | 1783628843620237312 |
---|---|
author | Sun, Weina McCroskery, Stephen Liu, Wen-Chun Leist, Sarah R. Liu, Yonghong Albrecht, Randy A. Slamanig, Stefan Oliva, Justine Amanat, Fatima Schäfer, Alexandra Dinnon, Kenneth H. Innis, Bruce L. García-Sastre, Adolfo Krammer, Florian Baric, Ralph S. Palese, Peter |
author_facet | Sun, Weina McCroskery, Stephen Liu, Wen-Chun Leist, Sarah R. Liu, Yonghong Albrecht, Randy A. Slamanig, Stefan Oliva, Justine Amanat, Fatima Schäfer, Alexandra Dinnon, Kenneth H. Innis, Bruce L. García-Sastre, Adolfo Krammer, Florian Baric, Ralph S. Palese, Peter |
author_sort | Sun, Weina |
collection | PubMed |
description | A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine. |
format | Online Article Text |
id | pubmed-7766959 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-77669592020-12-28 A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine Sun, Weina McCroskery, Stephen Liu, Wen-Chun Leist, Sarah R. Liu, Yonghong Albrecht, Randy A. Slamanig, Stefan Oliva, Justine Amanat, Fatima Schäfer, Alexandra Dinnon, Kenneth H. Innis, Bruce L. García-Sastre, Adolfo Krammer, Florian Baric, Ralph S. Palese, Peter Vaccines (Basel) Article A successful severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine must not only be safe and protective, but must also meet the demand on a global scale at a low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent coronavirus disease 2019 (COVID-19) vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine. MDPI 2020-12-17 /pmc/articles/PMC7766959/ /pubmed/33348607 http://dx.doi.org/10.3390/vaccines8040771 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sun, Weina McCroskery, Stephen Liu, Wen-Chun Leist, Sarah R. Liu, Yonghong Albrecht, Randy A. Slamanig, Stefan Oliva, Justine Amanat, Fatima Schäfer, Alexandra Dinnon, Kenneth H. Innis, Bruce L. García-Sastre, Adolfo Krammer, Florian Baric, Ralph S. Palese, Peter A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title_full | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title_fullStr | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title_full_unstemmed | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title_short | A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine |
title_sort | newcastle disease virus (ndv) expressing a membrane-anchored spike as a cost-effective inactivated sars-cov-2 vaccine |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7766959/ https://www.ncbi.nlm.nih.gov/pubmed/33348607 http://dx.doi.org/10.3390/vaccines8040771 |
work_keys_str_mv | AT sunweina anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT mccroskerystephen anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT liuwenchun anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT leistsarahr anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT liuyonghong anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT albrechtrandya anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT slamanigstefan anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT olivajustine anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT amanatfatima anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT schaferalexandra anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT dinnonkennethh anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT innisbrucel anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT garciasastreadolfo anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT krammerflorian anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT baricralphs anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT palesepeter anewcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT sunweina newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT mccroskerystephen newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT liuwenchun newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT leistsarahr newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT liuyonghong newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT albrechtrandya newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT slamanigstefan newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT olivajustine newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT amanatfatima newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT schaferalexandra newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT dinnonkennethh newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT innisbrucel newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT garciasastreadolfo newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT krammerflorian newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT baricralphs newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine AT palesepeter newcastlediseasevirusndvexpressingamembraneanchoredspikeasacosteffectiveinactivatedsarscov2vaccine |